Growth Metrics

Inhibikase Therapeutics (IKT) Other Non-Current Liabilities (2026)

Inhibikase Therapeutics (IKT) has 1 years of Other Non-Current Liabilities data on record, last reported at $400000.0 in Q1 2026.